Three shortlistings in eight years sounds modest until you add the context: CluePoints won the Scrip Awards Best Contract Research Organization (Specialist Providers) category in both 2023 and 2025, making this year’s finalist position a return trip as a defending two-time winner rather than a challenger looking to break through.
The Scrip Awards carry weight in clinical operations circles because they are peer-nominated and editorially judged, not pay-to-play. A repeat finalist in the same category signals that the judges see a consistent body of work, not a one-cycle product launch. CluePoints has built that record on statistical and AI-driven risk-based quality management software, a space where vendor differentiation is genuinely hard to communicate to evaluators who have seen a decade of “smart monitoring” pitches.
The timing matters for the company’s commercial positioning. CluePoints recently launched three AI-driven clinical data review capabilities, co-developed with a top-10 pharmaceutical company, covering intelligent query detection, medical and safety review, and medical coding. Bringing a co-innovation story with a major sponsor into awards season gives the company a concrete reference point that a shortlisting alone cannot provide. It also coincides with the appointment of Martin Magazzolo as Chief Commercial Officer in July, suggesting an active push to convert recognition into signed contracts.
Watch whether the 2026 win comes through. A third Scrip category win in four years would make CluePoints the benchmark name buyers cite when justifying RBQM vendor selection to procurement committees, and that kind of repetition in a specialist category is what shifts a platform from “considered” to “default.”
Source link: https://cluepoints.com/cluepoints-shortlisted-for-2026-scrip-awards-for-the-third-time-in-eight-years/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
